Objectives: The pharmacokinetics of infliximab (IFX) is highly variable in children with Crohn disease (CD), and a one-size-fits-all approach to dosing is inadequate. Model-based drug dosing can help individualize dosing strategies. We evaluated the predictive performance and clinical utility of a published population pharmacokinetic model of IFX in children with CD. Methods: Within a cohort of 34 children with CD who had IFX trough concentrations measured, the pharmacokinetics of each patient was estimated in NONMEM using a published population pharmacokinetic model. Infliximab concentrations were then predicted based on each patient's dosing history and compared with actual measured concentrations (n ¼ 59). In addition, doses 5 to 10 mg/kg and dosing intervals every 4 to 8 weeks were simulated in each patient to examine dose-trough relationships. Results: Predicted concentrations were within AE1.0 mg/mL of actual measured concentrations for 88% of measurements. The median prediction error (ie, measure of bias) was À0.15 mg/mL (95% confidence interval À0.37 to À0.05 mg/mL) and absolute prediction error (ie, measure of precision) was 0.26 mg/mL (95% confidence interval 0.15 to 0.40 mg/mL). At standard maintenance dosing of 5 mg/kg every 8 weeks, a trough >3 mg/mL was predicted to be achieved in 32% of patients. To achieve a trough >3 mg/mL, a dosing interval every 6 weeks was predicted to be required in 29% of patients. Conclusions: A published IFX population pharmacokinetic model demonstrated accurate predictive performance in a pediatric CD population. Individualized IFX dosing strategies in children with CD will be critical to consistently achieve trough concentrations associated with optimal outcomes.
I
nfliximab is the most commonly used first-line biologic agent for the treatment of moderate to severe Crohn disease (CD) in children. The current standard infliximab (IFX) maintenance dosing in children of 5 mg/kg every 8 weeks is based on the original randomized clinical trials demonstrating efficacy in adults and children with CD (1, 2) . The pharmacokinetics of IFX in children with CD is, however, highly variable, and a one-size-fits-all approach to dosing will not result in similar exposures across patients (3) . This variation in IFX exposure is clinically relevant. There is increasing evidence in adults and children that adequate
What Is Known
Infliximab pharmacokinetics is highly variable in children with Crohn disease, and a one-size-fits-all dosing will lead to large differences in drug exposure. Population pharmacokinetic models and therapeutic drug monitoring can guide individualized dosing strategies to ensure adequate drug exposure.
What Is New
We evaluated the predictive performance of a previously published population pharmacokinetic model in 34 Crohn disease children receiving infliximab who had drug concentrations measured. The pharmacokinetic mode predicted infliximab trough concentrations within AE1.0 mg/mL of actual infliximab trough concentrations for 88% of measurements. Standard infliximab 5 mg/kg every 8 weeks dosing predicted a trough concentration >3 mg/mL in only 32% of patients-necessitating increased dosing or frequency in the majority of patients to achieve adequate drug exposure.
IFX exposure is critical when treating CD, and trough concentrations <3 mg/mL are associated with treatment failure and worse outcomes (4) (5) (6) (7) (8) (9) (10) .
To better understand IFX dose-exposure relationships, we recently conducted a pharmacokinetic modeling and simulation analysis in children with CD and demonstrated that at the standard IFX dosing of 5 mg/kg every 8 weeks >60% of children were predicted to have a trough concentration <3 mg/mL (11) . Higher IFX doses and/or shorter dosing intervals were predicted to be needed to consistently achieve a trough concentration >3 mg/mL during maintenance dosing. Similarly, a prospective observational study found that 44% (n ¼ 10/23) of children with Crohn disease had a trough concentration <3 mg/mL when receiving standard IFX maintenance dosing of 5 mg/kg every 8 weeks (12) . Together, these studies highlight the need for more individualized dosing strategies of IFX in CD to ensure adequate exposure and account for the pharmacokinetic variation between patients.
To develop individualized IFX dosing strategies in patients, utilization of therapeutic drug monitoring (TDM) and population pharmacokinetic models will be essential (13) . TDM has already been successfully implemented in the clinical care of patients with inflammatory bowel disease and is a component of some treatment guidelines (14) (15) (16) (17) . In addition, several commercial assays that measure serum IFX concentrations are readily available. Similarly, a population pharmacokinetic model for IFX in CD patients was previously developed using data from 112 children in the REACH (A Randomized, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of Anti-TNF-Chimeric Monoclonal Antibody in Pediatric Subjects with Moderate-to-Severe Crohn's Disease) trial and 580 adults in the ACCENT (A Crohn's Disease Clinical Trial Evaluating Infliximab in a New, Long-term Treatment Regimen) I trial (3) . In this pharmacokinetic model, weight (WT), serum albumin, antibodies to IFX, and concomitant immunomodulation therapy (IMM) all significantly impacted IFX clearance, and consideration of these clinical characteristics may help optimize a patient's individual dose need. Before such model-based dosing can, however, be applied to aid in therapeutic decision making, ''validation'' of the underlying population pharmacokinetic model is critical (ie, can the model accurately and precisely predict drug concentrations in the patient population it will be applied?). The primary aim of the present study was to evaluate the predictive performance and clinical utility of a previously published IFX population pharmacokinetic model within a cohort of 34 children with CD receiving IFX. The secondary aim of the analysis was to examine the relationship between dosing strategy and trough concentration achievement in each patient to shed further light on dose needs in this population.
METHODS

Patient Cohort
To evaluate the predictive performance of the IFX population pharmacokinetic model, data from a previously collected prospective cohort of children <18 years with CD receiving IFX maintenance treatment were examined (12) . Patients in the cohort were enrolled consecutively at 2 academic hospitals and 1 district hospital in the Netherlands for a 1-year period. All patients had previously responded to an induction regimen with 5 mg/kg IFX at week 0, 2, and 6 followed by infusions every 8 weeks (q8w). There were no exclusion criteria. The original study was approved by the institutional review boards at all sites.
In each patient, IFX trough concentrations were measured before 2 consecutive IFX infusions. Additional laboratory data collected included antibodies to IFX (ATI), C-reactive protein, and serum albumin. Clinical data collected included WT, age, sex, and concomitant IMM. Infliximab serum concentrations and ATIs were determined by Sanquin Diagnostics Services (Amsterdam, the Netherlands) using a well-established enzyme-linked immunosorbent assay-based test (18) . This method did not allow detection of ATIs in the presence of IFX. The lower limit of quantification of IFX was 0.002 mg/mL.
Model Evaluation
A published IFX population pharmacokinetic model developed from 112 children in the REACH trial and 580 adults in the ACCENT I trial was implemented in the non-linear mixedeffects modeling software NONMEM 7.2 (ICON Development Solutions, Ellicott City, MD) (3). Briefly, a 2-compartment model with first-order elimination was used to describe IFX pharmacokinetics. Clearance (CL) was predicted according to the following equation: ). After accounting for known predictors, the remaining variation between children was described by an exponential error model for CL (% coefficient of variation [% CV] 30.7%), Vc (12.6%), and Vp (% CV 55.3%). Residual variability was captured using a combined proportional (% CV 29.2%) and additive error model (standard deviation [SD] AE 0.371 mg/mL).
For each patient, predicted IFX concentrations were simulated using the population pharmacokinetic model and dosing history. Predictions were calculated in 2 ways: using a patient's clinical characteristics only (ie, population prediction) and using a patient's clinical characteristics and IFX concentrations (ie, individual Bayesian prediction). Concentrations were simulated only at times for which a patient had IFX concentrations measured. The predicted concentrations were then compared with the corresponding observed IFX concentrations.
The bias and precision of the model were assessed by calculating the median prediction error and median absolute prediction error according to the following formulas (19) :
The 95% confidence interval (CI) of the median prediction error and median absolute prediction error were estimated using a bootstrap re-sampling procedure of 1000 replication datasets. The percentage of predicted concentrations within AE1 mg/mL of the observed concentration was also calculated.
Lastly, to evaluate the model's hypothetical application in the clinical setting, the ability of the model to predict a patient's second IFX concentration (measured after the next dose) using only the first concentration was calculated in the same manner as described above but limiting the dataset to only include the patient's first IFX concentration when estimating a patient's individual Bayesian prediction.
Dosing Strategy and Trough Concentration Achievement
Following model evaluation, the relationship between trough concentration and dosing strategy was examined. The individual Bayesian pharmacokinetic parameter estimates for each patient were used to calculate steady-state trough concentrations after different IFX maintenance dosing strategies. Doses of 5, 7.5, and 10 mg/kg at dosing intervals of every 4, 6, and 8 weeks were examined. Predicted IFX trough concentrations achieved in each patient were then summarized. In addition, the percentage of children that achieved a trough concentration >3 and >5 mg/mL were calculated for each IFX dosing strategy. Lastly, the minimum dosing strategy for each patient that resulted in a trough concentration >3 and >5 mg/mL was assessed. To account for both dose amount and dosing interval, dosing strategies were converted to mg Á kg À1 Á week À1 when evaluating the minimum dosing strategy. Target trough concentrations of >3 and > 5 mg/mL were chosen based on previous reports noting an association with treatment response (4) (5) (6) (7) (8) (9) (10) . Statistical analyses of the data and figure productions were performed using STATA 13 (StataCorp LP, College Station, TX).
RESULTS
Patient Cohort
Overall, data from a total of 34 children with CD were available for analysis. Demographic and clinical characteristics of the children are shown in Table 1 . The median (interquartile range [IQR]) IFX dose was 5.0 (5.0-5.0) mg/kg and median (IQR) dosing interval was 7.9 (7.0-8.0) weeks. Three (9%) patients received a dose of 10 mg/kg, and 7 (21%) patients had a dosing interval <7 weeks. Two trough concentrations were measured in 25 (74%) children, and 1 trough concentration was measured in 9 (26%) children.
Model Evaluation
When using only a patient's clinical characteristics to predict IFX concentration (ie, population prediction), the pharmacokinetic model predicted the observed IFX concentrations with low precision and accuracy ( Fig. 1A ; Table 2 ). For the population predictions, the median prediction error (ie, measure of bias) was À0.57 mg/mL (95% CI À1.4 to 0.03 mg/mL) and the median absolute prediction error (ie, measure of precision) was 1.3 mg/mL (95% CI 1.0 to 1.8 mg/mL). Only 36% of population predictions were within AE1 mg/mL of the observed concentration.
When including a patient's trough concentration(s) to predict IFX concentration (ie, individual Bayesian prediction), the predictive performance of the pharmacokinetic model improved and was able to adequately predict the observed IFX concentrations ( Fig. 1B; Table 2 ). For the individual Bayesian predictions, the median prediction error was À0.15 mg/mL (95% CI À0.37 to À0.05 mg/mL) and the median absolute prediction error was 0.26 mg/mL (95% CI 0.15 to 0.40 mg/mL). Individual predicted concentrations were within AE1.0 and AE1.5 mg/mL of the observed concentrations for 88% and 95% of measurements.
The ability of the pharmacokinetic model to predict a patient's second trough concentration using only the first trough concentration was evaluated in 25 patients (Fig. 1C) . The median prediction error was 0.07 mg/mL (95% CI À0.44 to 0.29 mg/mL) and the median absolute prediction error was 0.47 mg/mL (95% CI 0.23 to 1.1 mg/mL). Predicted concentrations were within AE1.0 and AE1.5 mg/mL of the observed concentrations for 68% and 88% of patients, respectively.
Dosing Strategy and Trough Concentration Achievement
The predicted trough concentrations in each patient for various dosing strategies are shown in Table 3 . At the standard IFX maintenance dosing of 5 mg/kg every 8 weeks, the median (IQR) predicted trough concentration was 2.2 (1.2-3.4) mg/mL, and a trough concentration >3 and >5 mg/mL was predicted to be achieved in 32% and 6% of patients, respectively. The trough concentration decreased as serum albumin decreased ( Fig. 2A) , and no patient who had a serum albumin 4 g/dL (n ¼ 0/7) was predicted to achieve a trough concentration >3 mg/mL at the standard IFX maintenance dosing of 5 mg/kg every 8 weeks. No trends in trough concentration achievement and patient WT (Fig. 2B) , sex (data not shown), or concomitant immunomodulatory status (data not shown) were seen.
The minimum dosing strategy needed in each patient to achieve a trough >3 and >5 mg/mL is shown in Figure 3 . To achieve a trough >3 and >5 mg/mL, a dosing interval every 6 weeks was predicted to be required in 29% and 62% of patients, respectively. Two patients did not achieve the target trough at even the highest dose examined (10 mg/kg every 4 weeks). Both patients had detectable antibodies to IFX. In the 2 other patients with detectable antibodies to IFX, the minimum dosing strategy needed to achieve a trough >3 mg/mL was 10 mg/kg every 6 weeks and 5 mg/kg every 4 weeks.
DISCUSSION
In this study, we demonstrate the predictive performance of a previously published population pharmacokinetic model for IFX in a prospectively followed cohort of children with CD. Overall, there was a high degree of agreement between model predicted and observed IFX concentrations, as indicated by the low prediction errors. Using only the clinical characteristics of a patient and 1 IFX drug concentration, the model could predict the subsequent IFX concentration of a patient within AE1.0 and AE1.5 mg/mL of the observed concentration for 68% and 88% of patients, respectively. This study represents the first published data to support the clinical application of a model-based approach to aid in the optimization of IFX dosing in children with CD. Population pharmacokinetic models offer a powerful tool to help individualize dosing based on a patient's unique pharmacokinetics (13) . The approach integrates patient-specific predictors of a drug's pharmacokinetics (ie, WT, serum albumin, concomitant immunomodulator therapy, IFX antibody status for IFX), dose history, and measured drug concentrations within a Bayesian framework to calculate an individualized dose most likely to achieve a defined exposure target for a patient (20) (21) (22) . Such model-based dosing has previously been shown to improve therapeutic target achievement, reduce hospital stay, reduce drug toxicity, and improve outcome when applied to other drugs (23) (24) (25) .
Similarly, there is great opportunity for model-based dosing to help advance therapeutic decision making for IFX in patients with CD. The pharmacokinetics of IFX are highly variable in this population and consequently dose requirements will vary between patients (3, 11) . In the cohort of children examined in the present study, the predicted IFX maintenance dosing strategy needed to achieve a trough concentration >3 mg/mL was heterogeneous and ranged from the standard dosing of 5 mg/kg every 8 weeks up to 5 mg/kg every 4 weeks (Fig. 3A) . Our cohort was homogenous in terms of serum albumin (only 1 patient had a serum albumin <3.5), Absolute prediction error is a measure of precision of the pharmacokinetic model. and serum albumin is the most influential predictor of IFX clearance and trough achievement (11) . Even greater heterogeneity in dose needs will likely be present in a larger, more diverse population. In addition, we demonstrated the potential challenges of achieving trough concentrations >3 mg/mL with even the most aggressive dosing (ie, 10 mg/kg every 4 weeks) in children who have developed antibodies to IFX. Taken together, more robust, model-based clinical dosing support tools are needed to help guide clinicians with dose individualization.
A challenge to date with model-based dosing is that most pharmacokinetic modeling software, such as NONMEM, is positioned better for research applications than clinical use. Several more user-friendly pharmacokinetic software programs are available, which have focused on antibiotic dosing (26) . Explorations are underway to develop a model-based clinical dosing support tool for IFX that highlights user experience and the potential for integration within the electronic medical record. The ability to develop and deliver a model-based dosing approach within the clinical workflow will be important for clinical adoption.
Previous retrospective and prospective studies, including randomized controlled trials, have shown the potential value of TDM to support IFX therapeutic decision making in adults with inflammatory bowel disease (14) (15) (16) 27) . Our study further highlights the value of TDM in the context of IFX dose individualization. With the availability of just 1 IFX concentration, the precision of the model improved by 60% compared with using clinical characteristics alone to predict a patient's dose-exposure relationship. Utilization of TDM will be an important clinical piece in individualizing the dosing strategy and ensuring adequate IFX exposure within a model-based framework.
A current challenge in the application of TDM in the clinical setting is the delayed turnaround time in measuring IFX concentrations. The current commercially available assays are often send out laboratories (eg, Prometheus 1 Anser 1 IFX) and can take several days to come back. As a result, the IFX concentration is not available to guide dosing decisions when drawn on the same day as the infusion. An advantage of model-based dosing is that the approach is robust in terms of the timing of when concentrations are measured and is not constrained to utilizing only a trough concentration. Therefore, the pharmacokinetics of a patient may be estimated using an IFX concentration measured several days to even weeks before the infusion. This would allow for the result to come back, and the individualized dose to then be calculated before the infusion. Nonetheless, even this approach is logistically cumbersome and not ideal from a patient convenience standpoint. In addition, further prospective validation of this approach would be necessary. The recent development of a bedside point-of-care IFX assay is promising and would alleviate many of these challenges (28) .
In our current study, we selected a trough concentration target >3 mg/mL along with a more aggressive target >5 mg/mL based on current evidence noting an association with treatment response (4) (5) (6) (7) (8) (9) (10) . The precise trough concentration to target in children with CD is, however, not clear. The model-based approach is agnostic to the specific trough concentration target chosen, and the clinician has the ability to adjust the target concentration. This flexibility will also allow for ongoing individualization as more specific trough concentration targets are established in patient subtypes. In addition, as new and innovative pharmacodynamic biomarkers of response are developed in inflammatory bowel disease (29) , our work serves as a framework to incorporate such pharmacodynamic biomarkers. The model-based approach can be continuously updated to reflect the current treatment goals and further advance individualized dosing strategies.
A limitation of the current study is the relatively small sample size of the cohort of children with CD available for validation. The true variation and distribution of potential children with CD was likely not captured. Nonetheless, external validation is the most rigorous method for testing a developed model (30) . Future real-world applications of the population pharmacokinetic model are necessary to assess the robustness of predicted IFX concentrations in diverse inflammatory bowel disease populations. For example, there appears to be a slight trend at higher concentrations for the model to under predict, and the ability of the model to predict concentrations in patients with low (or high) IFX clearance warrants further evaluation. In addition, because the pharmacokinetics of IFX in children with CD is unique and complex, performance of the model in adult CD patients and ulcerative colitis patients, in general, is yet to be determined but underway. Minimum dose needed to achieve trough >3 µg/mL A B FIGURE 3. Minimum infliximab dose predicted to be needed for each patient to achieve a trough concentration (A) >3 mg/mL or (B) >5 mg/mL in a cohort of children with Crohn disease (n ¼ 34 patients). For each patient, all dosing strategies were examined and the minimum dose that resulted in a trough concentration >3 and >5 mg/mL was selected. Two patients did not achieve the target infliximab trough concentration at even the highest dose examined 10 mg/kg every 4 weeks. Both patients had detectable antibodies for infliximab. IFX ¼ infliximab.
In conclusion, our study further supports the clinical rationale to individualize IFX dosing in patients with CD. A one-size-fitsall IFX dosing strategy results in subtherapeutic IFX trough levels in the majority of CD patients. Individualization of IFX dosing will be critical to consistently achieve trough concentrations associated with optimal outcomes. The application of a population pharmacokinetic model to aid in the optimization of IFX dosing in children with CD was also supported. Incorporation of such a model-based approach into a robust clinical dosing support tool can help guide clinicians with dose individualization.
